Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia

E-ISSN： 1873-5576|16|8|689-700

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.16, Iss.8, 2016-10, pp. : 689-700

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenalidomide in lymphomas and chronic lymphocytic leukemia

By Wiernik Peter H

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 475-488

Informa Healthcare

Access to resources Recommend Favorite

Bendamustine for treatment of chronic lymphocytic leukemia

By Chang Julie Elizabeth Kahl Brad Steven

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1495-1505

Informa Healthcare

Access to resources Recommend Favorite

New treatment options for chronic lymphocytic leukemia

By Delgado Julio Baumann Tycho Santacruz Rodrigo Montserrat Emili

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 823-832

Informa Healthcare

Access to resources Recommend Favorite

Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia

Current Cancer Drug Targets, Vol. 8, Iss. 2, 2008-03 ,pp. : 156-171

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Current Drug Delivery, Vol. 9, Iss. 1, 2012-01 ,pp. : 30-40

Bentham Science Publishers

Access to resources Recommend Favorite